Sadnasankar138: Adding entry

2026-04-13T10:07:03Z

Adding entry

New page

{{Short description|Indian multinational pharmaceutical company}}
{{EngvarB|date=January 2016}}
{{Use dmy dates|date=January 2016}}
{{Infobox company
| name = Lupin Limited
| logo = The Lupin Logo.svg
| logo_size = 150px
| caption =
| type = [[Public company|Public]]
| traded_as = {{BSE|500257}}<br />{{NSE|LUPIN}}
| genre =
| fate =
| predecessor =
| successor =
| foundation = {{Start date and age|1968}}<ref>{{cite web |url=http://www.lupinworld.com/history-milestone.htm |title=Welcome to Lupin World |publisher=Lupinworld.com |access-date=2013-05-30 |archive-url=https://web.archive.org/web/20120608075617/http://www.lupinworld.com/history-milestone.htm |archive-date=8 June 2012 |url-status=dead }}</ref>
| founder = [[Desh Bandhu Gupta]]<ref name="livemint1">{{cite web|url=http://www.livemint.com/2010/02/08000106/Lupin-goes-all-out-to-make-up.html |title=Lupin goes all out to make up for lost chances - Corporate News |publisher=livemint.com |date=2010-02-08 |access-date=2010-09-30}}</ref>
| defunct =
| location_city = [[Mumbai]], [[Maharashtra]]<ref>{{cite web |url=http://www.lupinworld.com/locations.htm |title=Welcome to Lupin World |publisher=Lupinworld.com |access-date=2013-05-30 |archive-url=https://web.archive.org/web/20130607164716/http://www.lupinworld.com/locations.htm |archive-date=7 June 2013 |url-status=dead }}</ref>
| location_country = India
| location =
| locations =
| area_served =
| key_people = [[Vinita D. Gupta]] (CEO)<ref name="ReferenceA">{{cite web|url=http://www.moneycontrol.com/news/announcements/lupin-outcomeboard-meeting_867214.html|title=Lupin outcome of board meeting|work=moneycontrol.com|date=8 May 2013 }}</ref><br />Nilesh Gupta (MD)<ref>{{Cite web|url=http://www.dnaindia.com/money/report-lupin-s-vinita-gupta-nilesh-gupta-win-ey-entrepreneur-award-2015-2176730|title = Lupin's Vinita Gupta, Nilesh Gupta win EY Entrepreneur Award 2015| work=dna |date = 12 February 2016}}</ref><ref>{{Cite web |url=http://www.lupin.com/management.php |title=Board of Directors |access-date=23 February 2016 |archive-date=7 October 2018 |archive-url=https://web.archive.org/web/20181007065813/http://lupin.com/management.php |url-status=dead}}</ref>
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| products = {{hlist|[[Medication|Pharmaceutical drugs]]| [[generic drug]]s| [[antiviral drug]]s| [[over-the-counter drug]]s| [[vaccine]]s| [[Medical diagnosis|diagnostics]]| [[contact lens]]es| [[Veterinary medicine|animal health]]| [[dietary supplements]] }}
| services =
| revenue = {{up}} {{INRConvert|22192|c}} (2025)
| operating_income = {{profit}} {{INRConvert|5277|c}} (2025)
| net_income = {{profit}} {{INRConvert|3281|c}} (2025)
| assets = {{profit}} {{INRConvert|29204|c}}
| assets_year = 2025
| equity = {{profit}} {{INRConvert|17294|c}}
| equity_year = 2025
| owner =
| num_employees = 20,000+
| num_employees_year = 2023
| parent =
| divisions =
| subsid =
| homepage = {{URL|http://www.lupin.com/}}
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Q4 FY2024-25 Presentation |url=https://www.lupin.com/wp-content/uploads/2025/05/lupin-q4fy25-investor-meet-presentation.pdf |publisher=Lupin |access-date=3 July 2025}}</ref><ref>{{cite web |title=Statement of audited consolidated financial results for the quarter and year ended March 31, 2025 |url=https://www.lupin.com/wp-content/uploads/2025/05/consolidated-q4fy25.pdf |publisher=Lupin |access-date=3 July 2025}}</ref>
}}

'''Lupin Limited''' is an Indian [[Multinational corporation|multinational]] [[pharmaceutical]] company based in [[Mumbai]]. It is primarily a manufacturer of [[generic drugs]], covering therapeutic areas such as [[paediatrics]], [[Circulatory system|cardiovascular]], [[Infection|anti-infectives]], [[Diabetes|diabetology]], [[asthma]] and [[Tuberculosis management|anti-tuberculosis]].The company operates in multiple international markets including the United States, Japan, Europe, and Australia..<ref>{{cite news |title=Top five generic drug makers |url=https://www.europeanpharmaceuticalreview.com/article/93095/top-five-generic-drug-makers/ |access-date=22 May 2020 |work=europeanpharmaceuticalreview.com}}</ref>

==History==
Lupin was founded in 1968 by [[Desh Bandhu Gupta]],<ref>{{cite news|url=https://www.forbes.com/profile/desh-bandhu-gupta/|title=Desh Bandhu Gupta|author=Megha Bahree|work=Forbes}}</ref> who was a professor of chemistry at [[BITS Pilani|BITS-Pilani]], [[Rajasthan]]. Gupta initially borrowed Rs. 5000 from his wife to fund the venture. Due to subsequent funding from the Central Bank of India, the company able to start their manufacturing facility for producing folic acid and iron tablets for the Indian government's mother and child health program. Later Lupin started manufacturing [[Tuberculosis management|anti-tuberculosis]] (TB) drugs which at one point formed 36% of the company sales and was considered as the largest TB drugs manufacturer in the world.<ref>{{Cite web|url=https://www.businesstoday.in/magazine/features/guru-of-generics/story/5661.html|title=Guru of Generics- Business News|website=businesstoday.in|date=26 May 2010 |access-date=2019-04-08}}</ref>

In 1988 Gupta founded the group's CSR arm, the Lupin Human Welfare & Research Foundation (LHWRF). This initiative was dedicated to sustainable rural development with the aim to uplift families living below the poverty line.<ref name="Bhatia">{{Cite web|url=https://officechai.com/stories/desh-bandhu-gupta-lupin-story/|title=How Desh Bandhu Gupta Turned A Rs. 5000 Loan Into The Rs. 18,000 Crore Pharmaceutical Giant, Lupin|last=Bhatia|first=Navin|date=2017-06-26|website=OfficeChai|access-date=2019-04-08}}</ref>

In 1999, Lupin joined the [[Indian Pharmaceutical Alliance]] as a founding member.<ref>{{Cite news |last=Dec 22 |first=PTI |date=2022-12-22 |title=Indian pharma sector set for 'volume to value leadership' journey in 2023 |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-sector-set-for-volume-to-value-leadership-journey-in-2023/articleshow/96407749.cms |access-date=2023-08-05 |issn=0013-0389}}</ref><ref>{{Cite web |title=Introducing IPA- Indian Pharmaceutical Alliance |url=https://www.ipa-india.org/about-ipa/introduction/ |access-date=2023-08-05 |website=IPA, Indian Pharmaceutical Alliance}}</ref>

In July 2015 the company announced its intention to acquire Gavis Pharmaceuticals and Novel Laboratories for $880 million.<ref>{{cite news|url=https://www.bloomberg.com/news/articles/2015-07-23/lupin-to-buy-gavis-in-880-million-deal-to-grow-in-u-s-generics|title=Lupin to Buy Gavis in $880 Million Deal to Expand in U.S.|author=Ketaki Gokhale|date=23 July 2015|work=Bloomberg.com}}</ref><ref>{{Cite web|url=http://www.genengnews.com/gen-news-highlights/lupin-acquires-gavis-pharmaceuticals-for-880m/81251544/|title = Lupin Acquires GAVIS Pharmaceuticals for $880M|date = 23 July 2015}}</ref>

The founder, Desh Bandhu Gupta died in June 2017 and was subsequently replaced as chairman by his wife, Manju Deshbandhu Gupta.<ref>{{Cite web|url=https://www.livemint.com/Companies/JNGBX52DBPh8dX7f1ENGcI/Lupin-appoints-Manju-Deshbandhu-Gupta-as-chairman.html|title=Lupin appoints Manju Deshbandhu Gupta as chairman|last=PTI|date=2017-08-11|website=Mint|language=en|access-date=2019-04-08}}</ref>

In October 2019, Lupin announced the Appointment of Sreeji Gopinatham as Chief Information Officer (CIO).<ref>{{cite news|url=https://business.medicaldialogues.in/sreeji-gopinathan-joins-lupin-as-chief-information-officer/|title= Sreeji Gopinathan joins Lupin as Chief Information Officer|date=October 10, 2019|work=Medical Dialogues}}</ref>

In March 2019, the US FDA put several Lupin drug plants on notice for quality problems, and indicated it might not approve future Lupin drug applications.

In May 2023, Lupin entered into an agreement to buy the French pharmaceutical company Medisol.<ref>{{Cite web |last=MENAFN |title=Lupin Announces Acquisition Of French Pharma Company Medisol |url=https://menafn.com/1106187941/Lupin-Announces-Acquisition-Of-French-Pharma-Company-Medisol |access-date=2023-08-05 |website=menafn.com |language=en}}</ref>

==Businesses==
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced [[drug delivery]] systems to biotechnology. The company's drugs reach 70 countries<ref>{{cite news|url=http://articles.economictimes.indiatimes.com/2010-04-30/news/27578338_1_kamal-k-sharma-lupin-generic-players|archive-url=https://web.archive.org/web/20140607010123/http://articles.economictimes.indiatimes.com/2010-04-30/news/27578338_1_kamal-k-sharma-lupin-generic-players|url-status=dead|archive-date=7 June 2014|title=Lupin transforms into a global pharma company|work=timesofindia-economictimes | date=2010-04-30}}</ref> with a footprint that covers advanced markets such as USA, Europe, Japan,<ref>{{cite web|url=http://forbesindia.com/article/my-learnings/the-japanese-are-a-brand-conscious-people-says-lupin-md/32892/1|title=Forbes India Magazine - The Japanese Are a Brand Conscious People, Says Lupin MD|work=forbesindia.com}}</ref> Australia as well as emerging markets including India, the Philippines and South Africa.

=== United States ===
Headquartered in [[Baltimore]], [[Maryland]], Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary is a $891 million enterprise.<ref>{{Cite web |url=http://www.lupin.com/pdf/15/FY15_Inv_ppt_13_May_15_vF.pdf |title=Archived copy |access-date=20 May 2015 |archive-date=17 October 2015 |archive-url=https://web.archive.org/web/20151017154538/http://www.lupin.com/pdf/15/FY15_Inv_ppt_13_May_15_vF.pdf |url-status=dead }}</ref> It has a presence in the branded and generics markets of the US. In the branded business, Lupin operates in the CVS and [[Pediatric]] segments. The company is the market leader in 28 products out of the 77 products marketed in the US generics market, of which it is amongst the Top 3 by market share in 57 of these products (IMS Health, December 2014): Suprax ([[Cefixime]]), a paediatric antibiotic, is Lupin's top-selling product here. Other products in Lupin's branded portfolio include Antara< ([[Fenofibrate]]), Locoid lotion, Alinia ([[Nitazoxanide]]) and InspiraChambers (Anti-static valved holding chamber). The company is also the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health). Lupin's US brands business contributed 9% of total US sales whereas the generics business contributed 91% during FY 2014–15.<ref>{{cite web|url=http://www.lupinworld.com/may-13-2015.php|title=Lupin|work=lupinworld.com}}</ref>

=== India Region Formulations (IRF) ===
Lupin's IRF business focuses on [[Lifestyle disease]]s and [[Chronic disease]] therapy segments, particularly in [[Cardiology]], [[Central Nervous System]] (CNS), [[Diabetes|Diabetology]], Anti-Asthma, Anti-Infective, Gastro Intestinal and [[Oncology]]. The IRF business contributed 24% of the company's overall revenues for FY 2014–15, growing by 20% and recording revenues of {{INRConvert|29676|m}} for FY 2014-15 as compared to {{INRConvert|24794|m}} for FY 2013–14.

It has 12 manufacturing plants and 2 Research plants in India, as [[Jam, Iran|Jammu]](J&K), Mandideep & Indore (Madhya pradesh), Ankaleswar & Dabasa (Gujarat), Tarapur, Aurangabad and Nagpur (Maharashtra), [[Goa]], [[Visakhapatnam]] (Andhra Pradesh) and [[Sikkim]]; where research centre at Pune and Aurangabad.<ref>{{cite web|url=http://www.lupinworld.com|title=Lupin|work=lupinworld.com|access-date=30 September 2010|archive-url=https://web.archive.org/web/20010225150934/http://www.lupinworld.com/|archive-date=25 February 2001|url-status=dead}}</ref>
Among these the baby plant is Nagpur plant which will the biggest formulation unit for Lupin in coming year.

=== Japan ===
Lupin operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company acquired in 2007,<ref>{{cite news|url=http://www.business-standard.com/article/companies/lupin-buys-japan-s-kyowa-pharma-107101101093_1.html|title=Lupin buys Japan's Kyowa Pharma|author=BS Reporter|date=11 October 2007|work=business-standard.com}}</ref><ref>{{cite news|url=https://www.reuters.com/article/idUSBMA00166120071010|title=India's Lupin says acquires Japan's Kyowa Pharma|work=Reuters | first=Himangshu|last=Watts|date=2007-10-10}}</ref> and I’rom, Pharmaceutical Co. Ltd (IP), acquired in 2011.<ref>{{cite web|url=http://www.indianexpress.com/news/lupin-acquires-japans-irom-pharma/877135/|title=Lupin acquires Japan's I'rom Pharma|work=indianexpress.com|date=17 November 2011}}</ref><ref>{{cite web|url=http://www.firstpost.com/fwire/lupin-to-acquire-japans-irom-pharma-133463.html|title=Lupin to acquire Japan's I'rom Pharma|work=Firstpost|date=17 November 2011}}</ref>

In 2014, Lupin entered into a strategic joint venture agreement with Toyama-based Japanese pharmaceuticals company, Yoshindo Inc. to create YL Biologics (YLB).<ref>{{cite web|url=http://www.livemint.com/Companies/VvNTuDeIPBuh6cVg23fuiM/Lupin-Yoshindo-to-form-new-JV-in-Japan-for-biological-drugs.html|title=Lupin, Yoshindo form JV for clinical development of biosimilars in Japan|author=C. H. Unnikrishnan|work=livemint.com|date=23 April 2014}}</ref>

In 2019, Lupin exited the generic pharmaceuticals business in Japan by divesting its stake in Kyowa to private equity firm Unison for an enterprise value of Japanese 57,361 million yen (Rs 3,702.4 crore).<ref>{{Cite news|title=Lupin sells Japan arm to Unison for Rs 3,702 cr, exits generic business|url=https://wap.business-standard.com/article/companies/lupin-sells-japan-arm-to-unison-for-rs-3-702-cr-exits-generic-business-119111101327_1.html}}</ref>

=== Australia ===
Lupin entered the Australian market through its subsidiary, Generic Health Pte. Ltd. (GH).<ref>{{cite news|url=http://www.business-standard.com/article/companies/lupin-acquires-majority-stake-in-australian-firm-110092900200_1.html|title=Lupin acquires majority stake in Australian firm|author=Press Trust of India|date=29 September 2010|work=business-standard.com}}</ref> It subsequently acquired the worldwide marketing rights to the over-100-year-old Australian brand Goanna,<ref>{{cite news|url=http://articles.economictimes.indiatimes.com/2011-06-15/news/29660505_1_lupin-brand-australian-market|archive-url=https://web.archive.org/web/20140606234702/http://articles.economictimes.indiatimes.com/2011-06-15/news/29660505_1_lupin-brand-australian-market|url-status=dead|archive-date=6 June 2014|title=Lupin acquires global rights for Australian brand Goanna|work=timesofindia-economictimes | date=2011-06-15}}</ref> used for pain management.

=== Philippines ===
Lupin's Philippines subsidiary Multicare Pharmaceuticals (Multicare),<ref>{{cite web|url=http://www.livemint.com/Companies/5NLXUi9cpTSregBAKxIqiM/Pharma--Lupin-buys-Philippines-drug-firm-Multicare.html|title=Pharma - Lupin buys Philippines drug firm Multicare|work=livemint.com|date=26 March 2009}}</ref> is a branded generic company focused on Women's Health, Pediatrics, Gastro-Intestinal and Diabetes care. FY 2012 also marked its foray into the Neurology segment when it entered into a strategic marketing partnership with Sanofi.<ref>{{cite web|url=http://www.livemint.com/Companies/LwG6AroDnFw5mqccKLsecL/Lupin-SanofiAventis-ink-drug-marketing-pact-in-Philippines.html|title=Lupin, Sanofi-Aventis ink drug marketing pact in Philippines|work=livemint.com|date=2 September 2011}}</ref>

=== Mexico & Latin America ===
In 2014, Lupin acquired 100% equity stake in Laboratories Grin, S.A. De C.V. (Grin), Mexico, a specialty pharmaceutical company engaged in the development, manufacturing and commercialization of branded ophthalmic products. This marked their entry into Mexico and the larger Latin American pharmaceuticals market. In May 2015, Lupin entered the Brazilian market with its acquisition of 100% stake in Medquímica Indústria Farmacêutica S.A., Brazil, (Medquímica).<ref>{{cite news|url=http://articles.economictimes.indiatimes.com/2015-05-13/news/62124190_1_drug-major-lupin-today-lupin-shares-vinita-gupta|archive-url=https://web.archive.org/web/20151010205414/http://articles.economictimes.indiatimes.com/2015-05-13/news/62124190_1_drug-major-lupin-today-lupin-shares-vinita-gupta|url-status=dead|archive-date=10 October 2015|title=Lupin acquires Brazilian drug firm Medquimica|work=timesofindia-economictimes | date=2015-05-13}}</ref>

==Corporate social responsibility==
The Lupin Human Welfare & Research Foundation (LHWRF) was set up in 1988. The project began with a set of rural development projects centred around 35 villages in [[Bharatpur, Rajasthan|Bharatpur District]], [[Rajasthan]]. Later this expanded to other regions and states. The initiative has so far reached out to over 2.8 million people across over 3,400 villages in eight states of India including Rajasthan, Madhya Pradesh, Maharashtra, Uttarakhand, Gujarat and Goa.<ref name="Bhatia"/> In July 2018, Lupin foundation signed a statement of Intent with the National Institution for Transforming India ([[NITI Aayog|Niti Aayog]]), a policy think tank of the government of India, to collaborate in the Aspirational Districts Programme and support the development of three backward districts – Nandurbar in Maharashtra, Vidisha in Madhya Pradesh and Dholpur in Rajasthan.<ref>{{cite web | url=http://pib.nic.in/newsite/PrintRelease.aspx?relid=180883 | title=Niti Aayog and Lupin foundation sign SoI | type=GOI press release | website=pib.nic.in}}</ref>

==References==
{{reflist|40em}}

==External links==
* {{Official website|http://www.lupin.com/}}

{{Nifty 200 companies}}
{{Authority control}}

[[Category:Manufacturing companies based in Mumbai]]
[[Category:Pharmaceutical companies established in 1968]]
[[Category:Pharmaceutical companies of India]]
[[Category:Indian companies established in 1968]]
[[Category:Indian brands]]
[[Category:1968 establishments in Maharashtra]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Multinational companies headquartered in India]]

Lupin (company) - Revision history

Sadnasankar138: Adding entry